Movement disorders drug pipelines

Abbvie

Duodopa Next Gen

Parkinson's disease

Phase III


Abbvie

Duodopa

Parkinson's disease

Approved


Abbvie

ABBV-8E12

Progressive supranuclear palsy

Phase I


Acorda

SYN120

Parkinson's disease

Phase II


Acorda

Tozadenant

Parkinson's disease

Phase III


Acorda

CVT-301

Parkinson's disease

Phase III


Dainippon Sumitomo Pharma

EPI-589

Parkinson's disease, ALS

Phase II


Dainippon Sumitomo Pharma

Zonisamide

Parkinson's disease

Phase III


Roche

RG6000

Amyotrophic lateral sclerosis

Phase I


Teva

deutetrabenazine

Tardive dyskinesia

Phase III


Teva

deuldopa

Parkinson's disease

Phase I


Pfizer

PF-06649751

Parkinson's disease

Modulator of dopamine signaling

Phase II


Otsuka

dextromethorphan, quinidine

Parkinson's disease dyskinesia

NMDA receptor antagonist/Serotonin and Norepinephrine reuptake inhibitor/Sigma-1 receptor agonist/Neuronal nicotinic receptor antagonist

Phase II


Biogen

BIIB067

SOD-1-Amyotrophic lateral sclerosis

Phase I


Biogen

BIIB054

Parkinson's disease

anti-α-synuclein

Phase I


AstraZeneca

AZD3241

Multiple system atrophy

myeloperoxidase inhibitor

Phase II


Roche

RG7935

Parkinson's disease

monoclonal antibody targeting alpha-synuclein

Phase I


Shire

TH/GCH1

Parkinson's disease

Preclinical


Teva & Takeda

Rasagiline

Parkinson's disease

Norepinephrine uptake inhibitor

Phase II


Acorda Therapeutics

CVT-301

Parkinson’s disease

Phase III


Biogen

Natalizumab

Secondary progressive multiple sclerosis

Phase III